Comprehensive NF1 screening on cultured Schwann cells from neurofibromas

被引:84
作者
Maertens, Ophelia
Brems, Hilde
Vandesompele, Jo
De Raedt, Thomas
Heyns, Ine
Rosenbaum, Thorsten
De Schepper, Sofie
De Paepe, Anne
Mortier, Geert
Janssens, Sandra
Speleman, Frank
Legius, Eric
Messiaen, Ludwine
机构
[1] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA
[2] Ghent Univ Hosp, Ctr Med Genet, Ghent, Belgium
[3] Catholic Univ Louvain, Ctr Human Genet, B-3000 Louvain, Belgium
[4] Univ Dusseldorf, Childrens Hosp, Dept Pediat, Dusseldorf, Germany
[5] Ghent Univ Hosp, Dept Dermatol, Ghent, Belgium
关键词
neurofibromatosis type 1; NF1; somatic mutation analysis;
D O I
10.1002/humu.20389
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Neurofibromatosis type 1 (NF1) is mainly characterized by the occurrence of benign peripheral nerve sheath tumors or neurofibromas. Thorough investigation of the somatic mutation spectrum has thus far been hampered by the large size of the NF1 gene and the considerable proportion of NF1 heterozygous cells within the tumors. We developed an improved somatic mutation detection strategy on cultured Schwann cells derived from neurofibromas and investigated 38 tumors from nine NF1 patients. Twenty-nine somatic NF1 lesions were detected which represents the highest NF1 somatic mutation detection rate described so far (76%). Furthermore, our data strongly suggest that the acquired second hit underlies reduced NF1 expression in Schwann cell cultures. Together, these data clearly illustrate that two inactivating NF1 mutations, in a subpopulation of the Schwann cells, are required for neurofibroma formation in NF1 tumorigenesis. The observed somatic mutation spectrum shows that intragenic NF1 mutations (26/29) are most prevalent, particularly frameshift mutations (12/29, 41%). We hypothesize that this mutation signature might reflect slightly reduced DNA repair efficiency as a trigger for NF1 somatic inactivation preceding tumorigenesis. joint analysis of the current and previously published NF1 mutation data revealed a significant difference in the somatic mutation spectrum in patients with a NF1 microdeletion vs. non-microdeletion patients with respect to the prevalence of loss of heterozygosity events (0/15 vs. 41/81). Differences in somatic inactivation mechanism might therefore exist between NF1 microdeletion patients and the general NF1 population.
引用
收藏
页码:1030 / 1040
页数:11
相关论文
共 76 条
[1]   Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2 [J].
Abaza, MM ;
Makariou, E ;
Armstrong, M ;
Lalwani, AK .
LARYNGOSCOPE, 1996, 106 (06) :694-699
[2]   THE NF1 LOCUS ENCODES A PROTEIN FUNCTIONALLY RELATED TO MAMMALIAN GAP AND YEAST IRA PROTEINS [J].
BALLESTER, R ;
MARCHUK, D ;
BOGUSKI, M ;
SAULINO, A ;
LETCHER, R ;
WIGLER, M ;
COLLINS, F .
CELL, 1990, 63 (04) :851-859
[3]  
Boland CR, 1998, CANCER RES, V58, P5248
[4]   Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells [J].
Bollag, G ;
Clapp, DW ;
Shih, S ;
Adler, F ;
Zhang, YY ;
Thompson, P ;
Lange, BJ ;
Freedman, MH ;
McCormick, F ;
Jacks, T ;
Shannon, K .
NATURE GENETICS, 1996, 12 (02) :144-148
[5]   GROWTH OF A RAT NEUROBLASTOMA CELL LINE IN SERUM-FREE SUPPLEMENTED MEDIUM [J].
BOTTENSTEIN, JE ;
SATO, GH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (01) :514-517
[6]   IDENTIFICATION AND CHARACTERIZATION OF TRANSCRIPTS FROM THE NEUROFIBROMATOSIS-1 REGION - THE SEQUENCE AND GENOMIC STRUCTURE OF EVI2 AND MAPPING OF OTHER TRANSCRIPTS [J].
CAWTHON, RM ;
OCONNELL, P ;
BUCHBERG, AM ;
VISKOCHIL, D ;
WEISS, RB ;
CULVER, M ;
STEVENS, J ;
JENKINS, NA ;
COPELAND, NG ;
WHITE, R .
GENOMICS, 1990, 7 (04) :555-565
[7]  
Cnossen MH, 1997, HUM MUTAT, V9, P458, DOI 10.1002/(SICI)1098-1004(1997)9:5<458::AID-HUMU13>3.0.CO
[8]  
2-1
[9]   BENIGN NEUROFIBROMAS IN TYPE-1 NEUROFIBROMATOSIS (NF1) SHOW SOMATIC DELETIONS OF THE NF1 GENE [J].
COLMAN, SD ;
WILLIAMS, CA ;
WALLACE, MR .
NATURE GENETICS, 1995, 11 (01) :90-92
[10]  
Correa CL, 1999, HUM MUTAT, V14, P387, DOI 10.1002/(SICI)1098-1004(199911)14:5<387::AID-HUMU4>3.0.CO